GPT and metabolic dysfunction-associated steatotic liver disease: Alterations in liver enzymes like ALT due to CKD have been reported before (Ray et al., 2015) and pioglitazone has been reported to lower ALT levels in patients with non-alcoholic fatty liver disease (Lian and Fu, 2021).